← Leaderboards
John S Lazo
University Of Pittsburgh At Pittsburgh
$20,744,955
Attributed
$20,744,955
Total exposure
21
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5.6M · FY2005–22$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$29,266,008 · 22
By mechanism
U54$10,064,496 · 1
P01$9,885,550 · 2
U19$3,736,478 · 5
R01$1,670,195 · 2
P30$1,130,753 · 2
T32$792,862 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Michael S. Diamond$85,358,908
- Saumendra N Sarkar$6,788,497
- Sanjay K Srivastava$3,005,777
- Brian I Carr$2,254,345
- Margaret Victoria Ragni$7,547,687
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadAntineoplasticsCellsSmall MoleculeDrug Screening /EvaluationInnovationSmall Molecule LibrariesIn VitroLibrariesDesignMalignant NeoplasmsLaboratory MouseBaseAnalogStructureInhibitor/AntagonistMolecular TargetPharmaceutical PreparationsDrug Design /Synthesis /ProductionScreening ProcedureBleomycinDrug DiscoveryPhosphoric Monoester HydrolasesFuture
Grant awards (80)
A PTP4A3 inhibitor for SARS-CoV-2-mediated acute lung injury$55,000
R43 · FY2022 · HL · contact PI
A PTP4A3 inhibitor for SARS-CoV-2-mediated acute lung injury$6,500
R43 · FY2022 · HL · contact PI
A PTP4A3 inhibitor for SARS-CoV-2-mediated acute lung injury$252,208
R43 · FY2021 · HL · contact PI
Developing small molecule PTP4A3 inhibitors for ovarian cancer$289,307
R43 · FY2019 · CA · contact PI
Operetta CLS High-content Imaging System$516,040
S10 · FY2017 · OD · contact PI
PTP4A3 as a Molecular Cancer Target$169,809
R21 · FY2015 · CA · contact PI
siRNA Library Screening for Pharmacologic Radiation Mitigators$278,847
U19 · FY2014 · AI · contact PI
PTP4A3 as a Molecular Cancer Target$204,174
R21 · FY2014 · CA · contact PI
CHEMICAL BIOLOGY FACILITY$123,232
P30 · FY2014 · CA · contact PI
siRNA Library Screening for Pharmacologic Radiation Mitigators$401,176
U19 · FY2013 · AI · contact PI
CHEMICAL BIOLOGY FACILITY$148,023
P30 · FY2013 · CA · contact PI
siRNA Library Screening for Pharmacologic Radiation Mitigators$395,776
U19 · FY2012 · AI · contact PI
CHEMICAL BIOLOGY FACILITY$168,380
P30 · FY2012 · CA · contact PI
siRNA Library Screening for Pharmacologic Radiation Mitigators$271,091
U19 · FY2011 · AI · contact PI
CHEMICAL BIOLOGY FACILITY$95,027
P30 · FY2011 · CA · contact PI
siRNA Library Screening for Pharmacologic Radiation Mitigators$268,820
U19 · FY2010 · AI · contact PI
CHEMICAL BIOLOGY FACILITY$95,283
P30 · FY2010 · CA · contact PI
Molecular Pharmacology & Biochemistry of Dual Specificity Phosphatase Inhibitors$300,978
P01 · FY2009 · CA · contact PI
Core--Innovative medicinal chemistry: discovery and screening$196,744
U19 · FY2009 · AI · contact PI
Combinatorial Approaches for Novel Anticancer Agents$75,559
P01 · FY2009 · CA · contact PI
Combinatorial Approaches for Novel Anticancer Agents$16,380
P01 · FY2009 · CA · contact PI
Combinatorial Approaches for Novel Anticancer Agents$1,263,625
P01 · FY2008 · CA · contact PI
Pittsburgh Molecular Libraries Screening Center(RMI)$757,500
U54 · FY2008 · MH · contact PI
Molecular Pharmacology & Biochemistry of Dual Specificity Phosphatase Inhibitors$276,044
P01 · FY2008 · CA · contact PI
Core--Innovative medicinal chemistry: discovery and screening$191,034
U19 · FY2008 · AI · contact PI
Combinatorial Approaches for Novel Anticancer Agents$84,840
P01 · FY2008 · CA · contact PI
Pittsburgh Molecular Libraries Screening Center(RMI)$3,721,893
U54 · FY2007 · MH · contact PI
Combinatorial Approaches for Novel Anticancer Agents$1,254,614
P01 · FY2007 · CA · contact PI
Molecular Pharmacology & Biochemistry of Dual Specificity Phosphatase Inhibitors$257,635
P01 · FY2007 · CA · contact PI
Core--Innovative medicinal chemistry: discovery and screening$211,888
U19 · FY2007 · AI · contact PI
Pittsburgh Molecular Libraries Screening Center(RMI)$160,309
U54 · FY2007 · MH · contact PI
Pittsburgh Molecular Libraries Screening Center(RMI)$3,346,967
U54 · FY2006 · MH · contact PI
Combinatorial Approaches for Novel Anticancer Agents$1,307,136
P01 · FY2006 · CA · contact PI
Core--Medicinal chemistry: discovery and screening$186,632
U19 · FY2006 · AI · contact PI
MOLECULAR PHARM. AND BIOCHEM. OF NOVEL DUAL SPECIIFICITY PHOSPHATASE INHIBITORS$170,406
P01 · FY2006 · CA · contact PI
Pittsburgh Molecular Libraries Screening Center(RMI)$19,926
U54 · FY2006 · MH · contact PI
Pittsburgh Molecular Libraries Screening Center(RMI)$2,057,901
U54 · FY2005 · MH
Combinatorial Approaches for Novel Anticancer Agents$1,268,693
P01 · FY2005 · CA
Core--Medicinal chemistry: discovery and screening$184,217
U19 · FY2005 · AI
MOLECULAR PHARM. AND BIOCHEM. OF NOVEL DUAL SPECIIFICITY PHOSPHATASE INHIBITORS$165,602
P01 · FY2005 · CA
CANCER STRESS RELEVANT PROTEIN PHOSPHATASE TARGETS$148,637
U19 · FY2005 · CA
Chemical Complementation Assay for MKP-1 (RMI)$4,455
R03 · FY2005 · MH
Chemical Complementation Assay for MKP-3 (RMI)$4,455
R03 · FY2005 · MH
In Vitro High Throughput Screening Assay for MKP-3(RMI)$4,455
R03 · FY2005 · MH
In Vitro High Throughput Screening Assay for MKP-1(RMI)$4,455
R03 · FY2005 · MH
Bleomycin Hydrolase and Alzheimer's Disease$274,554
R01 · FY2004 · AG
PREDOCTORAL TRAINING IN PHARMACOLOGICAL SCIENCES$141,891
T32 · FY2004 · GM
COMBINATORIAL APPROACHES FOR NOVEL ANTICANCER AGENTS$124,688
P01 · FY2004 · CA
Bleomycin Hydrolase and Alzheimer's Disease$275,727
R01 · FY2003 · AG
PREDOCTORAL TRAINING IN PHARMACOLOGICAL SCIENCES$174,178
T32 · FY2003 · GM
COMBINATORIAL APPROACHES FOR NOVEL ANTICANCER AGENTS$1,051,840
P01 · FY2002 · CA
Bleomycin Hydrolase and Alzheimer's Disease$276,882
R01 · FY2002 · AG
CORE--CELL FLUORESCENT BIOSENSOR$250,404
U19 · FY2002 · CA
PRECLINICAL EVALUATION OF MACROMOLECULAR THERAPEUTICS$250,404
U19 · FY2002 · CA
Molecular therapeutics and drug discovery program$250,404
P30 · FY2002 · CA
PREDOCTORAL TRAINING IN PHARMACOLOGICAL SCIENCES$166,350
T32 · FY2002 · GM
Bleomycin hydroase in AD$158,272
P50 · FY2002 · AG
MOLECULAR PHARMACOLOGY AND BIOCHEMISTRY OF ANTIPHOSPHATES$0
P01 · FY2002 · CA
COMBINATORIAL APPROACHES FOR NOVEL ANTICANCER AGENTS$1,078,228
P01 · FY2001 · CA
Bleomycin Hydrolase and Alzheimer's Disease$270,248
R01 · FY2001 · AG
BIOCHEMICAL REGULATORS OF BLEOMYCIN INDUCED TUMORS$259,158
R01 · FY2001 · CA
PRECLINICAL EVALUATION OF MACROMOLECULAR THERAPEUTICS$250,404
U19 · FY2001 · CA
Molecular therapeutics and drug discovery program$250,404
P30 · FY2001 · CA
CORE--CELL FLUORESCENT BIOSENSOR$250,404
U19 · FY2001 · CA
PREDOCTORAL TRAINING IN PHARMACOLOGICAL SCIENCES$158,332
T32 · FY2001 · GM
Bleomycin hydroase in AD$158,272
P50 · FY2001 · AG
BIOCHEMICAL REGULATORS OF BLEOMYCIN INDUCED TUMORS$22,742
R01 · FY2001 · CA
PRECLINICAL EVALUATION OF MACROMOLECULAR THERAPEUTICS$0
U19 · FY2001 · CA
CORE--CELL FLUORESCENT BIOSENSOR$0
U19 · FY2001 · CA
Molecular therapeutics and drug discovery program$0
P30 · FY2001 · CA
MOLECULAR PHARMACOLOGY AND BIOCHEMISTRY OF ANTIPHOSPHATES$0
P01 · FY2001 · CA
COMBINATORIAL APPROACHES FOR NOVEL ANTICANCER AGENTS$995,450
P01 · FY2000 · CA
BIOCHEMICAL REGULATORS OF BLEOMYCIN INDUCED TUMORS$252,903
R01 · FY2000 · CA
MOLECULAR PHARMACOLOGY AND BIOCHEMISTRY OF ANTIPHOSPHATES$193,832
P01 · FY2000 · CA
Bleomycin hydroase in AD$158,272
P50 · FY2000 · AG
PREDOCTORAL TRAINING IN PHARMACOLOGICAL SCIENCES$152,111
T32 · FY2000 · GM
BIOCHEMICAL REGULATORS OF BLEOMYCIN INDUCED TUMORS$37,981
R01 · FY2000 · CA
Molecular therapeutics and drug discovery program$0
P30 · FY2000 · CA
CORE--CELL FLUORESCENT BIOSENSOR$0
U19 · FY2000 · CA
PRECLINICAL EVALUATION OF MACROMOLECULAR THERAPEUTICS$0
U19 · FY2000 · CA